ECM
CYTK icon

Everence Capital Management’s Cytokinetics CYTK Stock Holding History

Everence Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Buy
4,328
+475
+12% +$34.1K 0.02% 550
2026
Q1 		$254K Sell
3,853
-227
-6% -$14.4K 0.02% 656
2025
Q4 		$259K Hold
4,080
– – 0.02% 651
2025
Q3 		$224K Buy
+4,080
New +$168K 0.01% 727
2024
Q1 		– Sell
-13,510
Closed -$1.13M – 763
2023
Q4 		$1.13M Hold
13,510
– – 0.08% 206
2023
Q3 		$398K Sell
13,510
-2,940
-18% -$97.9K 0.03% 454
2023
Q2 		$620K Hold
16,450
– – 0.05% 304
2023
Q1 		$579K Hold
16,450
– – 0.05% 326
2022
Q4 		$754K Hold
16,450
– – 0.07% 259
2022
Q3 		$797K Hold
16,450
– – 0.07% 233
2022
Q2 		$646K Buy
16,450
+2,550
+18% +$103K 0.06% 264
2022
Q1 		$512K Hold
13,900
– – 0.04% 385
2021
Q4 		$634K Hold
13,900
– – 0.05% 338
2021
Q3 		$497K Buy
13,900
+3,700
+36% +$109K 0.04% 405
2021
Q2 		$202K Hold
10,200
– – 0.02% 699
2021
Q1 		$237K Sell
10,200
-4,710
-32% -$101K 0.02% 637
2020
Q4 		$310K Hold
14,910
– – 0.03% 504
2020
Q3 		$323K Sell
14,910
-1,470
-9% -$34.4K 0.04% 436
2020
Q2 		$339K Hold
16,380
– – 0.04% 417
2020
Q1 		$193K Hold
16,380
– – 0.03% 522
2019
Q4 		$174K Hold
16,380
– – 0.03% 633
2019
Q3 		$186K Hold
16,380
– – 0.03% 584
2019
Q2 		$184K Hold
16,380
– – 0.03% 585
2019
Q1 		$133K Buy
+16,380
New +$120K 0.02% 602

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Everence Capital Management's CYTK Position: Q2 2026 in Review

Everence Capital Management increased its Cytokinetics (CYTK) stake by 12% in Q2 2026, buying an estimated $34.1K and bringing the position to 4,328 shares worth $369K. The position accounts for 0.02% of the portfolio, ranked #550.

Everence Capital Management first reported a position in CYTK in Q1 2019 and has held it in 24 quarters since. The position peaked at $1.13M in Q4 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Everence Capital Management held 4,328 shares of Cytokinetics worth $369K as of Q2 2026.
  • Everence Capital Management bought 475 Cytokinetics shares in Q2 2026, an estimated $34.1K.
  • Cytokinetics made up 0.02% of Everence Capital Management's portfolio in Q2 2026, its #550 holding.
  • Everence Capital Management first reported a position in Cytokinetics in Q1 2019 and has held it in 24 quarters since.
  • Everence Capital Management's Cytokinetics position peaked at $1.13M in Q4 2023.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Everence Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.